DGAP-News
MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): AGM/EGM
MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the
Supervisory Board (news with additional features)
30.07.2015 / 16:55
---------------------------------------------------------------------
PRESS RELEASE N 12 / 2015 of 07/30/2015
MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory
Board
Berlin, July 30, 2015 - At yesterday's Annual General Meeting of the
biotechnology company MOLOGEN AG, Oliver Krautscheid was reelected as a
member of the Supervisory Board. In addition, the Supervisory Board once
again unanimously voted Oliver Krautscheid to the position of Chairman of
the Supervisory Board. Stefan M. Manth, MD, will remain in the role of Vice
Chairman. The shareholders also approved the main items on the agenda.
The voting results and further information on the Annual General Meeting
can be found on the company website under:
http://www.mologen.com/en/investor-relations-press/annual-general-meeting.
html
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immunotherapies and DNA vaccines against
infectious diseases.
The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
small cell lung cancer (randomized controlled trial). A second
clinical-stage product is MGN1601, a therapeutic vaccination for the
treatment of renal cancer. A phase I/II clinical study has already been
completed successfully.
For more information on the trials please visit www.clinicaltrials.gov.
With unique, patented technologies and innovative products, MOLOGEN is
pioneering immuno- therapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)
MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=HYUSYIOLIJ
Document title: MOLOGEN AG: Oliver Krautscheid reelected as Chairman
of the Supervisory Board
---------------------------------------------------------------------
30.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
382487 30.07.2015
PRESS RELEASE N 12 / 2015 of 07/30/2015
MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory
Board
Berlin, July 30, 2015 - At yesterday's Annual General Meeting of the
biotechnology company MOLOGEN AG, Oliver Krautscheid was reelected as a
member of the Supervisory Board. In addition, the Supervisory Board once
again unanimously voted Oliver Krautscheid to the position of Chairman of
the Supervisory Board. Stefan M. Manth, MD, will remain in the role of Vice
Chairman. The shareholders also approved the main items on the agenda.
The voting results and further information on the Annual General Meeting
can be found on the company website under:
http://www.mologen.com/en/investor-relations-press/annual-general-meeting.
html
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immunotherapies and DNA vaccines against
infectious diseases.
The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
small cell lung cancer (randomized controlled trial). A second
clinical-stage product is MGN1601, a therapeutic vaccination for the
treatment of renal cancer. A phase I/II clinical study has already been
completed successfully.
For more information on the trials please visit www.clinicaltrials.gov.
With unique, patented technologies and innovative products, MOLOGEN is
pioneering immuno- therapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)
MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=HYUSYIOLIJ
Document title: MOLOGEN AG: Oliver Krautscheid reelected as Chairman
of the Supervisory Board
---------------------------------------------------------------------
30.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
382487 30.07.2015
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte